Bylvay now approved in Canada to treat adults, children with Alagille
Bylvay (odevixibat), an oral medication used to treat cholestatic pruritus — severe itching that results from a buildup of bile acids used in digestion —…
News
FDA OKs clinical trials to test cell therapy for chronic hepatitis B
The U.S. Food and Drug Administration (FDA) has given Lion TCR the green light to start Phase 1b/2 clinical trials testing LioCyx-M004, the clinical-stage…
PBC treatment Ocaliva leaves U.S. market amid safety concerns
Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…
Hormone-like therapy NF-1 shows promise in ICP mouse study
Nesfatin-1 (NF-1), a hormone-like molecule that may ease cellular stress, reduced injury to the placenta in a mouse model of intrahepatic cholestasis of pregnancy…
FDA weighs noninvasive biopsy alternative in MASH clinical trials
The U.S. Food and Drug Administration (FDA) will evaluate the use of Fibroscan, a noninvasive test, to replace liver biopsies in clinical trials for metabolic…
Virtual 5K expands annual run into national biliary atresia fundraiser
An annual fundraising run in the Washington area becomes a monthlong, virtual event this year to raise funds and awareness for the rare pediatric liver…
Phase 3 Trial of brelovitug for hepatitis D enrolls 1st patient
The first participant has been enrolled in a Phase 3 clinical trial testing Bluejay Therapeutics’ investigational therapy brelovitug against bulevirtide in adults with chronic…
Groups unite to fight liver disease during PBC Awareness Month
Members of the primary biliary cholangitis (PBC) community have come together in September as part of PBC Awareness Month to build support and share…
LSR gene mutations may cause new type of rare liver disease PFIC
Mutations in the LSR gene, including one previously unreported, were the likely cause of progressive familial intrahepatic cholestasis (PFIC) in two young children in Turkey,…
Alcohol consumption disrupts protein that controls liver fat: Study
Exposure to excessive alcohol disrupts the activity of a protein that plays a key role in keeping liver fat healthy, a study found. Researchers said…
Recent Posts
- Livmarli eases Alagille teen’s itch following liver transplant issues
- US enrollment starts for hepatitis B gene therapy clinical trial
- Women with PBC may be at high risk of disease flares after childbirth
- Agrimonolide shows benefits in cholestasis mouse model
- The health risks of soda, including liver damage, are increasingly clear